<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04459715</url>
  </required_header>
  <id_info>
    <org_study_id>Debio 1143-SCCHN-301</org_study_id>
    <secondary_id>2020-000377-25</secondary_id>
    <nct_id>NCT04459715</nct_id>
  </id_info>
  <brief_title>A Study of Debio 1143 in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy</brief_title>
  <official_title>A Randomized, Double-Blind Placebo-Controlled, Phase 3 Study of Debio 1143 in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Debiopharm International SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GORTEC (Head and Neck Oncology and Radiotherapy Group)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Debiopharm International SA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to demonstrate superior efficacy of Debio 1143 vs
      placebo when added to chemoradiotherapy (CRT) in locally advanced squamous cell carcinoma of
      the head and neck (LA-SCCHN).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 15, 2020</start_date>
  <completion_date type="Anticipated">April 30, 2027</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2027</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event-Free Survival (EFS)</measure>
    <time_frame>From randomization to the earliest between any EFS event (death or progression or primary treatment failure or relapse after achieving complete response or second cancers) or End of study (EOS); (within 60 months post randomization)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>From randomization to the earliest between PFS event or EOS (within 60 months post randomization)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Locoregional Control (LRC)</measure>
    <time_frame>From randomization to the earliest between PFS event (progression at the site of the primary tumor or the locoregional lymph nodes) or EOS (within 60 months post randomization)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>From randomization to the earliest between progression, start of a new anticancer therapy for this disease or participant's EOS (within 12 months post randomization)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Response Rate (CRR)</measure>
    <time_frame>From randomization to the earliest between progression, start of a new anticancer therapy for this disease or participant's EOS (within 12 months post randomization)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DoR)</measure>
    <time_frame>From first evidence of response (partial or complete) to the earliest between DoR event (progression) or EOS (within 24 months post first evidence of response)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>From randomization to the earliest between death or EOS (within 60 months post randomization)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Radical Salvage Surgery</measure>
    <time_frame>From randomization to the earliest between radical salvage surgery or EOS (within 60 months post randomization)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Subsequent Systemic Cancer Treatments</measure>
    <time_frame>From randomization to EOS (within 60 months post randomization)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events (AEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs)</measure>
    <time_frame>From signed informed consent to EOS (within 6.8 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Clinically Significant Laboratory Abnormalities Assessed by NCI-CTCAE v 5.0</measure>
    <time_frame>From signed informed consent to EOS (within 6.8 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Clinically Significant Vital Signs Assessed by NCI-CTCAE v 5.0</measure>
    <time_frame>From signed informed consent to EOS (within 6.8 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Clinically Significant Electrocardiograms Assessed by NCI-CTCAE v 5.0</measure>
    <time_frame>From signed informed consent to EOS (within 6.8 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extent of exposure</measure>
    <time_frame>From first study treatment dose to End of Treatment (EOT); (Up to 15 days after Cycle 6 (each cycle is of 15 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in Quality of Life and Fatigue using European Organisation for Research and Treatment of Cancer Quality of life Questionnaire (EORTC QLQ-C30) Score</measure>
    <time_frame>From randomization to EOS (within 60 months post randomization)</time_frame>
    <description>The EORTC QLQ-C30 version 3.0 questionnaire captures Health-Related Quality of Life (HRQL) dimensions that are common to cancer participants independently of the cancer type by which they are affected. The total scores are transformed from 0 to 100, where higher score indicates better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in Swallowing and Pain using EORTC QLQ Head and Neck Cancer Module (EORTC QLQ-HN35) Score</measure>
    <time_frame>From randomization to EOS (within 60 months post randomization)</time_frame>
    <description>The EORTC QLQ-HN35 is a disease-specific module capturing HRQL dimensions that affect head and neck cancer patients. The total scores are transformed from 0 to 100, where higher score indicates more severe symptoms.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">700</enrollment>
  <condition>Carcinoma, Squamous Cell of the Head and Neck</condition>
  <arm_group>
    <arm_group_label>Debio 1143</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a combination of Debio 1143 orally daily for 14 days for Cycles 1-3 (each cycle is of 15 days) along with IMRT 5 days/7 for Cycles 1-3 and cisplatin on infusion once per cycle for Cycles 1-3, followed by monotherapy of Debio 1143 once daily from Days 1 to 14 for Cycles 4-6.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo matched to Debio 1143 once daily along with IMRT 5 days/7 for Cycles 1-3 and cisplatin on infusion once per cycle for Cycles 1-3, followed by a monotherapy of placebo matched to Debio 1143 once daily from Days 1 to 14, for Cycles 4-6.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Debio 1143</intervention_name>
    <description>Debio 1143 oral solution for Cycles 1-6.</description>
    <arm_group_label>Debio 1143</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Cisplatin concentrate for solution for infusion for Cycles 1-3.</description>
    <arm_group_label>Debio 1143</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Intensity Modulation Radiation Therapy (IMRT)</intervention_name>
    <description>5 days/7 for Cycles 1-3.</description>
    <arm_group_label>Debio 1143</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matched to Debio 1143 oral solution for Cycles 1-6.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Eastern Cooperative Oncology Group performance status (ECOG PS) 0 or 1

          -  Histologically confirmed diagnosis in previously untreated Locally Advanced Squamous
             Cell Carcinoma of the Head and Neck (LA-SCCHN) participant (stage III, IVa or IVb
             according to the American Joint Committee on Cancer(AJCC))/Classification of malignant
             tumors: T=size of the primary tumor, N=regional lymph node involvement, M=distant
             metastasis (TNM) Staging System, 8th Ed.) suitable for definitive ChemoRadiotherapy
             (CRT), of at least one of the following sites: oropharynx, hypopharynx and larynx

          -  For OroPharyngeal Cancer (OPC) participants, primary tumors must be human
             papillomavirus (HPV)-negative as determined by p16 expression using
             immunohistochemistry

          -  Evaluable tumor burden (measurable and/or non-measurable tumor lesions) assessed by
             computed tomography scan (CT-scan) or magnetic resonance imaging (MRI), based on
             RECIST v 1.1

          -  Peripheral neuropathy &lt; grade 2

          -  Adequate hematologic, renal and hepatic function

        Exclusion Criteria:

          -  Primary tumor of nasopharyngeal, paranasal sinuses, nasal or oral cavity, salivary,
             thyroid or parathyroid gland pathologies, skin or unknown primary site

          -  Metastatic disease (stage IVc as per AJCC/TNM, 8th Ed.)

          -  Prior definitive or adjuvant Radiotherapy (RT) and/or radical surgery to the head and
             neck region which may jeopardize the primary tumor irradiation plan, or any other
             prior SCCHN systemic treatment, including investigational agents

          -  Documented weight loss of &gt;10% during the last 4 weeks prior to randomization (unless
             adequate measures are undertaken for nutritional support), OR plasmatic albumin &lt; 3.0
             g/dL

          -  Known allergy to Debio 1143, cisplatin or any excipient known to be present in
             Debio1143 or in the placebo formulation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Debiopharm International S.A</last_name>
    <phone>+41 21 321 01 11</phone>
    <email>clinicaltrials@debiopharm.com</email>
  </overall_contact>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 30, 2020</study_first_submitted>
  <study_first_submitted_qc>July 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 7, 2020</study_first_posted>
  <last_update_submitted>July 3, 2020</last_update_submitted>
  <last_update_submitted_qc>July 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

